Format

Send to

Choose Destination
J Med Econ. 2016;19(3):236-42. doi: 10.3111/13696998.2015.1113979. Epub 2015 Nov 19.

Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.

Author information

1
a a HEVA HEOR , Lyon , France.
2
b b Ossian Health Economics and Communications , Basel , Switzerland.
3
c c Medtronic UK , Watford , UK.
4
d d Medtronic International Trading Sàrl , Tolochenaz , Switzerland.
5
e e Faculty of Life Sciences and Medicine , King's College London, Guy's Hospital , London , UK.

Abstract

AIMS/HYPOTHESIS:

Continuous subcutaneous insulin infusion (CSII) is an important treatment option for type 1 diabetes patients unable to achieve adequate glycemic control with multiple daily injections (MDI). Combining CSII with continuous glucose monitoring (CGM) in sensor-augmented pump therapy (SAP) with a low glucose-suspend (LGS) feature may further improve glycemic control and reduce the frequency of hypoglycemia. A cost-effectiveness analysis of SAP + LGS vs. CSII plus self-monitoring of blood glucose (SMBG) was performed to determine the health economic benefits of SAP + LGS in type 1 diabetes patients using CSII in the U.K.

METHODS:

Cost-effectiveness analysis was performed using the CORE diabetes model. Treatment effects were sourced from the literature, where SAP + LGS was associated with a projected HbA1c reduction of -1.49% vs. -0.62% for CSII, and a reduced frequency of severe hypoglycemia. The time horizon was that of patient lifetimes; future costs and clinical outcomes were discounted at 3.5% and 1.5% per annum, respectively.

RESULTS:

Projected outcomes showed that SAP + LGS was associated with higher mean quality-adjusted life expectancy (17.9 vs. 14.9 quality-adjusted life years [QALYs], SAP + LGS vs. CSII), and higher life expectancy (23.8 vs. 21.9 years), but higher mean lifetime direct costs (GBP 125,559 vs. GBP 88,991), leading to an incremental cost-effectiveness ratio (ICER) of GBP 12,233 per QALY gained for SAP + LGS vs. CSII. Findings of the base-case analysis remained robust in sensitivity analyses.

CONCLUSIONS/INTERPRETATION:

For UK-based type 1 diabetes patients with poor glycemic control, the use of SAP + LGS is likely to be cost-effective compared with CSII plus SMBG.

KEYWORDS:

Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Cost-effectiveness; Sensor-augmented pump therapy; Type 1 diabetes

PMID:
26510389
DOI:
10.3111/13696998.2015.1113979
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center